

Cover Story
By Claire Dietz and Matthew Bin Han Ong
The Cancer Prevention and Research Institute of Texas—the second largest publicly-funded granting organization for cancer after NIH—may receive $3 billion more to stay open past its current sunset date in 2023.
Conversation with The Cancer Letter
By Claire Dietz and Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time















